Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Supira Medical
Entity

Supira Medical

Tracked across 1 events · 7 articles · First seen Apr 08, 2026 · Last active Apr 08, 2026

Sentiment
70
Attention
4
Events
1
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 70
Tech
Supira Medical FDA Approval for pVAD Trial
Supira Medical received FDA approval to initiate its SUPPORT II Pivotal Trial for its next-generation pVAD, a critical step towards U.S. market entry. The company also announced advances in treating cardiogenic shock and appointed D. Keith Grossman to its Board of Directors, strengthening its commercial foundation and market readiness.
Apr 08, 2026 · 7 articles
Key Actions (3)
100 United States===Food and Drug Administration approved initiation of pivotal trial Supira MedicalSupira Medical FDA...
90 Supira Medical initiated SUPPORT II Pivotal TrialSupira Medical FDA...
70 Supira Medical appointed to Board of Directors D. Keith GrossmanSupira Medical FDA...
Relationships (2)
Nitin Salunke President and CEO ↔ Supira Medical Nitin Salunke is the President and CEO of Supira Medical.
D. Keith Grossman Board Member ↔ Supira Medical D. Keith Grossman is an independent board member of Supira Medical.
NEWSDESK
Track Supira Medical live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.